OncoMatch/Clinical Trials/NCT06593665
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
Is NCT06593665 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Inrathecal Morphine and Intravenous Methadone for testicular cancer.
Treatment: Inrathecal Morphine · Intravenous Methadone — This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. Investigators plan to compare their analgesic effectiveness at different postoperative time intervals.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Testicular Germ Cell Tumor
Performance status
ASA 1–3
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Indiana Univeristy · Indianapolis, Indiana
- Indiana University Hospital · Indianapolis, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06593665 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages